Palatin Technologies Inc. – Material Contracts Watch

from 10-Q 70 pages Research Collaboration, License and Patent Assignment Agreement by and Between Boehringer Ingelheim International Gmbh and Palatin Technologies, Inc. Bi Contract No: [*] 1 Research Collaboration, License and Patent Assignment Agreement

from 10-K 19 pages 1.0 Term of Employment. the Company Hereby Agrees to Continue Employing the Employee, and the Employee Hereby Accepts the Continuation of Employment With the Company, Upon the Terms Set Forth in This Agreement, for the Period Commencing on July 1, 2025 (The “Commencement Date”) and Ending on June 30, 2028 Unless Sooner Terminated in Accordance With the Provisions of Section 4 (The “Employment Period”). 2.0 Position Title & Capacity. 2.1 the Employee Shall Serve as Chief Financial Officer and Chief Operating Officer, With Responsibilities Consistent With This Position and as the Company’s Board of Directors (The "Board") May Determine From Time to Time, With Powers and Duties as May Be Determined, From Time to Time, by the Board, Consistent With the Employee’s Position. the Employee Shall Report to the Company’s Board of Directors. the Employee Shall Be Based at the Company’s Corporate Headquarters, Which Is Based in Cranbury, New Jersey. the Employee Shall Also Be Available for Travel at Such Times and to Such Places as May Be Reasonably Necessary in Connection With the Performance of His Duties Hereunder. 2.2 the Employee May Serve as an Employee Director on the Board as Determined and Approved by the Board During the Employment Period and for No Additional Compensation; However, Upon Termination of Employment for Any Reason, the Employee Will No Longer Serve as a Member of the Company’s Board of Directors and Will Take Any and All Actions Necessary to Effectuate Such Resignation as May Be Reasonably Requested by the Company

from 10-K 19 pages 1.0 Term of Employment. the Company Hereby Agrees to Continue Employing the Employee, and the Employee Hereby Accepts the Continuation of Employment With the Company, Upon the Terms Set Forth in This Agreement, for the Period Commencing on July 1, 2025 (The “Commencement Date”) and Ending on June 30, 2028 Unless Sooner Terminated in Accordance With the Provisions of Section 4 (The “Employment Period”). 2.0 Position Title & Capacity. 2.1 the Employee Shall Serve as Chief Executive Officer and President, With Responsibilities Consistent With This Position and as the Company’s Board of Directors (The “Board”) May Determine From Time to Time, With Powers and Duties as May Be Determined, From Time to Time, by the Board, Consistent With the Employee’s Position. the Employee Shall Report to the Company’s Board of Directors. the Employee Shall Be Based at the Company’s Corporate Headquarters, Which Is Based in Cranbury, New Jersey. the Employee Shall Also Be Available for Travel at Such Times and to Such Places as May Be Reasonably Necessary in Connection With the Performance of His Duties Hereunder. 2.2 the Employee May Serve as an Employee Director on the Board as Determined and Approved by the Board During the Employment Period and for No Additional Compensation; However, Upon Termination of Employment for Any Reason, the Employee Will No Longer Serve as a Member of the Company’s Board of Directors and Will Take Any and All Actions Necessary to Effectuate Such Resignation as May Be Reasonably Requested by the Company

from 8-K 15 pages Securities Purchase Agreement

from 8-K 33 pages Securities Purchase Agreement

from S-1/A 33 pages Securities Purchase Agreement

from S-1 8 pages A.G.P./ALLIANCE Global Partners 590 Madison Avenue, 28th Floor New York, Ny 10022 and Laidlaw & Company (Uk) Ltd. 521 5th Ave, New York, Ny 10175 March [ ], 2025 Palatin Technologies, Inc. 4b Cedar Brook Drive Cranbury, New Jersey 08512 Attention: Carl Spana, PH.D., President and Chief Executive Officer Re: Placement Agency Agreement Dear Dr. Spana

from S-1 31 pages Securities Purchase Agreement

from 8-K 32 pages Securities Purchase Agreement

from 8-K 11 pages December 13, 2024 to the Holder of Common Stock Purchase Warrants Re: Inducement Offer to Exercise Existing Common Stock Purchase Warrants Dear Holder

from 8-K 8 pages June 20, 2024 to the Holder of Common Stock Purchase Warrants Re: Inducement Offer to Exercise Existing Common Stock Purchase Warrants Dear Holder

from 10-Q 52 pages Specific Terms in This Exhibit Havebeen Redacted Because (1) Such Terms Are Both Not Material and Are the Type That the Registrant Treats as Privateor Confidential; or (2) Disclosure of Such Information Would Constitutea Clearly Unwarranted Invasion of Personal Privacy. These Redacted Terms Have Been Marked in This Exhibit With Two Asterisks [**]. Asset Purchase Agreement Between Cosette Pharmaceuticals, Inc. and Palatin Technologies, Inc. Dated as of December 19, 2023

from 8-K 42 pages Securities Purchase Agreement

from 8-K 44 pages Securities Purchase Agreement

from 10-K 14 pages Palatin Technologies, Inc. 2011 Stock Incentive Plan, as Amended and Restated

from 8-K 37 pages Securities Purchase Agreement

from 8-K 18 pages 2.0 Position Title & Capacity

from 8-K 18 pages 2.0 Position Title & Capacity

from 10-Q 17 pages Common Stock Purchase Warrant Palatin Technologies, Inc

from 10-Q 17 pages Common Stock Purchase Warrant Palatin Technologies, Inc